Hsp90-dependent assembly of the DBC2/RhoBTB2-cullin3 E3-ligase complex

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Manjarrez, Jacob R ^a,b   Sun, Liang ^a,c   Prince, Thomas ^a,d   Matts, Robert L ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c NANJING UNIVERSITY   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CULLIN; CULLIN3 E3 UBIQUITIN LIGASE COMPLEX; DBC2 PROTEIN; GELDANAMYCIN; GUANOSINE TRIPHOSPHATE; HEAT SHOCK PROTEIN 90; MOLYBDIC ACID; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CUL3 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN BINDING; RHOBTB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; LIQUID CHROMATOGRAPHY; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TANDEM MASS SPECTROMETRY; CELL LINE; GENETICS; HUMAN; IMMUNOPRECIPITATION; MASS SPECTROMETRY; METABOLISM;

CELL LINE; CULLIN PROTEINS; GTP-BINDING PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; MASS SPECTROMETRY; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84897510781     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090054     Document Type: Article

References (69)

1. American Cancer Society. Breast Cancer Facts & Figures 2011-2012. Atlanta: American Cancer Society I.
2. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, et al. (2008) Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer 113: 2627-2637.
3. Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9: 321-345.
4. Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, et al. (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99: 13647-13652. (Pubitemid 35215435)
5. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, et al. (1996) Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 56: 2411-2416. (Pubitemid 26154091)
6. Swalwell JI, Vocke CD, Yang Y, Walker JR, Grouse L, et al. (2002) Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer 33: 201-205. (Pubitemid 34052501)
7. Brown MR, Chuaqui R, Vocke CD, Berchuck A, Middleton LP, et al. (1999) Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. Gynecol Oncol 74: 98-102. (Pubitemid 29331174)
8. Lerebours F, Olschwang S, Thuille B, Schmitz A, Fouchet P, et al. (1999) Fine deletion mapping of chromosome 8p in non-small-cell lung carcinoma. Int J Cancer 81: 854-858. (Pubitemid 29249967)
9. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, et al. (1992) Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 52: 5368-5372.
10. Lerebours F, Olschwang S, Thuille B, Schmitz A, Fouchet P, et al. (1999) Deletion mapping of the tumor suppressor locus involved in colorectal cancer on chromosome band 8p21. Genes Chromosomes Cancer 25: 147-153. (Pubitemid 29226597)
11. Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, et al. (1993) Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 53: 1172-1174. (Pubitemid 23087925)
12. Knowles MA, Shaw ME, Proctor AJ (1993) Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 8: 1357-1364. (Pubitemid 23129860)
13. Jones TD, Eble JN, Wang M, Maclennan GT, Jain S, et al. (2005) Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer 104: 1195-1203. (Pubitemid 41278954)
14. Shi Y, Chen JY, Yang J, Li B, Chen ZH, et al. (2008) DBC2 gene is silenced by promoter methylation in bladder cancer. Urol Oncol 26: 465-469.
15. Dong W, Meng L, Shen HC, Du JJ (2012) Loss of DBC2 expression is an early and progressive event in the development of lung adenocarcinoma. Asian Pac J Cancer Prev 13: 2021-2023.
16. Hajikhan Mirzaei M, Noruzinia M, Karbassian H, Shafeghati Y, Keyhanee M, et al. (2012) Evaluation of Methylation Status in the 59UTR Promoter Region of the DBC2 Gene as a Biomarker in Sporadic Breast Cancer. Cell J 14: 19-24.
17. Han L, Hou L, Song J, Lin D, Wu L, et al. (2013) Decreased expression of the DBC2 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation. Biotechnol Lett 35: 1175-1181.
18. Berthold J, Schenkova K, Rivero F (2008) Rho GTPases of the RhoBTB subfamily and tumorigenesis. Acta Pharmacol Sin 29: 285-295. (Pubitemid 351316996)
19. Cho YG, Choi BJ, Kim CJ, Song JH, Zhang C, et al. (2008) Genetic analysis of the DBC2 gene in gastric cancer. Acta Oncol 47: 366-371. (Pubitemid 351414917)
20. Knowles MA, Aveyard JS, Taylor CF, Harnden P, Bass S (2005) Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett 225: 121-130. (Pubitemid 40732775)
21. Freeman SN, Cress WD (2010) RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biol Ther 10: 1123-1125.
22. Albagli O, Dhordain P, Deweindt C, Lecocq G, Leprince D (1995) The BTB/POZ domain: a new protein-protein interaction motif common to DNA-and actin-binding proteins. Cell Growth Differ 6: 1193-1198.
23. Perez-Torrado R, Yamada D, Defossez PA (2006) Born to bind: the BTB protein-protein interaction domain. Bioessays 28: 1194-1202. (Pubitemid 44925439)
24. Siripurapu V, Meth J, Kobayashi N, Hamaguchi M (2005) DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J Mol Biol 346: 83-89. (Pubitemid 40128308)
25. Yoshihara T, Collado D, Hamaguchi M (2007) Cyclin D1 down-regulation is essential for DBC2's tumor suppressor function. Biochem Biophys Res Commun 358: 1076-1079. (Pubitemid 46828997)
26. Freeman SN, Ma Y, Cress WD (2008) RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J Biol Chem 283: 2353-2362.
27. Garritano S, Inga A, Gemignani F, Landi S (2013) More targets, more pathways and more clues for mutant p53. Oncogenesis 2: e54.
28. McKinnon CM, Lygoe KA, Skelton L, Mitter R, Mellor H (2008) The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells. Oncogene 27: 6856-6865.
29. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, et al. (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156: 1937-1950. (Pubitemid 30641763)
30. Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K 2nd, et al. (1999) Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255: 703-706. (Pubitemid 29294862)
31. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, et al. (2004) BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 64: 8262-8270. (Pubitemid 39496830)
32. Chang FK, Sato N, Kobayashi-Simorowski N, Yoshihara T, Meth JL, et al. (2006) DBC2 is essential for transporting vesicular stomatitis virus glycoprotein. J Mol Biol 364: 302-308. (Pubitemid 44715940)
33. Ling LJ, Lu C, Zhou GP, Wang S (2010) Ectopic expression of RhoBTB2 inhibits migration and invasion of human breast cancer cells. Cancer Biol Ther 10: 1115-1122.
34. Pintard L, Willems A, Peter M (2004) Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J 23: 1681-1687. (Pubitemid 38649631)
35. van den Heuvel S (2004) Protein degradation: CUL-3 and BTB-partners in proteolysis. Curr Biol 14: R59-61. (Pubitemid 38203910)
36. Willems AR, Schwab M, Tyers M (2004) A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta 1695: 133-170. (Pubitemid 39574971)
37. Berthold J, Schenkova K, Ramos S, Miura Y, Furukawa M, et al. (2008) Characterization of RhoBTB-dependent Cul3 ubiquitin ligase complexes-evidence for an autoregulatory mechanism. Exp Cell Res 314: 3453-3465.
38. Wilkins A, Carpenter CL (2008) Regulation of RhoBTB2 by the Cul3 ubiquitin ligase complex. Methods Enzymol 439: 103-109.
39. Wilkins A, Ping Q, Carpenter CL (2004) RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase complex. Genes Dev 18: 856-861. (Pubitemid 38529655)
40. Collado D, Yoshihara T, Hamaguchi M (2007) DBC2 resistance is achieved by enhancing 26S proteasome-mediated protein degradation. Biochem Biophys Res Commun 360: 600-603. (Pubitemid 47048141)
41. Shao J, Hartson SD, Matts RL (2002) Evidence that protein phosphatase 5 functions to negatively modulate the maturation of the Hsp90-dependent heme-regulated eIF2alpha kinase. Biochemistry 41: 6770-6779. (Pubitemid 34547368)
42. Craig D, Howell MT, Gibbs CL, Hunt T, Jackson RJ (1992) Plasmid cDNA-directed protein synthesis in a coupled eukaryotic in vitro transcription-translation system. Nucleic Acids Res 20: 4987-4995.
43. Hartson SD, Irwin AD, Shao J, Scroggins BT, Volk L, et al. (2000) p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules. Biochemistry 39: 7631-7644. (Pubitemid 30422083)
44. Prince T, Shao J, Matts RL, Hartson SD (2005) Evidence for chaperone heterocomplexes containing both Hsp90 and VCP. Biochem Biophys Res Commun 331: 1331-1337. (Pubitemid 40692502)
45. Matts RL, Manjarrez JR (2009) Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action. Curr Top Med Chem 9: 1462-1478.
46. Prince T, Matts RL (2004) Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37. J Biol Chem 279: 39975-39981. (Pubitemid 39258271)
47. Prince T, Sun L, Matts RL (2005) Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry 44: 15287-15295. (Pubitemid 41681463)
48. Scroggins BT, Prince T, Shao J, Uma S, Huang W, et al. (2003) High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients. Biochemistry 42: 12550-12561. (Pubitemid 37337545)
49. Paduch M, Jelen F, Otlewski J (2001) Structure of small G proteins and their regulators. Acta Biochim Pol 48: 829-850. (Pubitemid 33602340)
50. Gano JJ, Simon JA (2010) A proteomic investigation of ligand-dependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting protein. Mol Cell Proteomics 9: 255-270.
51. Kato JY, Yoneda-Kato N (2009) Mammalian COP9 signalosome. Genes to cells: devoted to molecular & cellular mechanisms 14: 1209-1225.
52. Enchev RI, Schreiber A, Beuron F, Morris EP (2010) Structural Insights into the COP9 Signalosome and Its Common Architecture with the 26S Proteasome Lid and eIF3. Structure 18: 518-527.
53. Kotiguda GG, Weinberg D, Dessau M, Salvi C, Serino G, et al. (2012) The organization of a CSN5-containing subcomplex of the COP9 signalosome. J Biol Chem 287: 42031-42041.
54. Echeverria PC, Picard D (2010) Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochimica et biophysica acta 1803: 641-649.
55. Pratt WB, Toft DO (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111-133. (Pubitemid 36187918)
56. Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, et al. (2006) Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 281: 2989-2998. (Pubitemid 43845766)
57. Felts SJ, Karnitz LM, Toft DO (2007) Functioning of the Hsp90 machine in chaperoning checkpoint kinase I (Chk1) and the progesterone receptor (PR). Cell Stress Chaperones 12: 353-363.
58. Pratt WB, Morishima Y, Osawa Y (2008) The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 283: 22885-22889.
59. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, et al. (2012) PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40: D261-270.
60. Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, et al. (2012) Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150: 987-1001.
61. Aspenstrom P, Ruusala A, Pacholsky D (2007) Taking Rho GTPases to the next level: the cellular functions of atypical Rho GTPases. Exp Cell Res 313: 3673-3679. (Pubitemid 47464235)
62. DerMardirossian C, Bokoch GM (2005) GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 15: 356-363. (Pubitemid 40943524)
63. Chardin P (2006) Function and regulation of Rnd proteins. Nat Rev Mol Cell Biol 7: 54.
64. Bosu DR, Kipreos ET (2008) Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Div 3: 7.
65. Cayli S, Klug J, Chapiro J, Frohlich S, Krasteva G, et al. (2009) COP9 signalosome interacts ATP-dependently with p97/valosin-containing protein (VCP) and controls the ubiquitination status of proteins bound to p97/VCP. J Biol Chem 284: 34944-34953.
66. Bennett EJ, Rush J, Gygi SP, Harper JW (2010) Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 143: 951-965.
67. Schultz J, Milpetz F, Bork P, Ponting CP (1998) SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci USA 95: 5857-5864. (Pubitemid 28248931)
68. Letunic I, Doerks T, Bork P (2012) SMART 7: recent updates to the protein domain annotation resource. Nucleic Acids Res 40: D302-305.
69. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, et al. (2012) The Pfam protein families database. Nucleic Acids Res 40: D290-301.